No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 15
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Cadrenal Therapeutics, Inc. Common Stock (CVKD) stock was $0.94 as of Oct 6, 2026, 12:24 PM EDT, down 0.91% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -93.2% · 3-year avg -54.1%/yr
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development.
Biotechnology · Ponte Vedra, FL
Next Earnings Date
Nov 9, 2026
34 days away
EPS Estimate
-0.91
Revenue Est.
N/A
Last Quarter Results
EPS
$-1.14
vs Estimate
$-0.95
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1CVKD | $3.34M | $0.94 | -0.91% | -93.24% | N/A | N/A | N/A |
| 2AEMD | $3.28M | $6.23 | -4.52% | -83.19% | -78.27% | -65.74% | vs CVKD |
| 3PAVS | $3.25M | $3.79 | +0.53% | -100.00% | -92.96% | N/A | vs CVKD |
| 4MLEC | $3.46M | $4.77 | -1.85% | -64.99% | -68.13% | N/A | vs CVKD |
| 5EOCN | $3.48M | $3.34 | -3.19% | N/A | N/A | N/A | vs CVKD |
| 6MBIO | $3.49M | $0.46 | +0.20% | -70.71% | -80.80% | N/A | vs CVKD |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 3 analysts
Average Price Target
$14.00
+1393.8% upside
Low
$12.00
Current
$0.94
High
$17.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.94 | $-0.91 | $-0.87 | 2 |
| Quarter ending Dec 2026 | $-0.89 | $-0.86 | $-0.82 | 2 |
| Quarter ending Mar 2027 | $-0.88 | $-0.88 | $-0.88 | 1 |
| Quarter ending Jun 2027 | $-0.90 | $-0.90 | $-0.90 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-3.92 | $-3.86 | $-3.76 | 2 |
| FY 2027 | $-3.55 | $-3.01 | $-2.21 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $6.30M | $6.30M | $6.30M | 3 |
